Dispute over 'miracle drugs': 6 peptides approved in US despite FDA opposition

An FDA expert committee recommended allowing pharmacies to compound six experimental peptides, despite objections from the FDA itself due to lack of data on their safety and efficacy in humans. The decision drew criticism over the committee's composition, which included individuals with interests in promoting peptides. The final decision rests with the FDA.

An FDA expert committee on pharmacy compounding recommended allowing pharmacies to compound six experimental peptides: BPC-157 (ulcerative colitis), KPV (wound healing), TB-500 (wound healing), MOTs-C (obesity, osteoporosis), Semax (neurological disorders), and Epitalon (insomnia). A seventh peptide, Emideltide, was rejected. FDA specialists opposed including any of them due to insufficient scientific data. The committee's composition drew criticism: it included seven owners and employees of clinics that prescribe or sell peptides, creating a conflict of interest. Supporters of the decision, including Health Secretary Robert Kennedy Jr., believe legalizing pharmacy compounding will help combat the gray market. Opponents fear it will create a false impression of safety. In Israel, opinions are divided: Dr. Daniel Gerstein points to the scarcity of clinical data, while Professor Tzipi Strauss calls the review a positive step. The final decision rests with the FDA.